$15 million was secured by Triomics, a San Francisco, California-based startup that is developing generative AI models to improve cancer clinics’ processes.
Investors
- Lightspeed
- Y Combinator
- General Catalyst
- Nexus Venture Partners
Use of funds
The money will be used by the business to grow both its operations and growth initiatives.
With the help of its OncoLLMTM, proprietary software that interfaces with EHRs in healthcare systems may do a variety of administrative and clinical functions. Triomics Prism, for instance, helps in patient-trial matching by using prescreening to identify clinical trials that are pertinent to cancer patients who have scheduled visits. EHR data is curated by Triomics Harmony to facilitate precision oncology, cohort analysis, and quality reporting.
Next, Triomics intends to create software that supports more use cases and release more data on the effectiveness of OncoLLM in a range of patient demographics and contexts.
About Triomics
Triomics, led by Sarim Khan, the CEO, and Hrituraj Singh, the CTO, creates generative AI models specifically tailored for oncology (OncoLLMTM) and uses case-specific software to assist cancer providers in processing large amounts of free-text health record data, matching patients to clinical trials, enhancing quality-of-care operations, and providing precision oncology.
“Our investments in our core areas of focus have been deliberate.” Our clinical personnel, with decades of experience in cancer, and our AI researchers, who specialize in tailoring language models to certain domains, have effectively combined their skills in two challenging functional areas. Thus, with the complexities of cancer research and care in mind, our software can both proactively fix any weaknesses and enhance the strengths of these sophisticated models.”
Hrituraj Singh
